Scholars Central

Conference abstractPublished 13 Sep 2017

Reappraise the association of dyslipidemia and CVD risk in T2DM: How to optimize statin therapy from the international guideline perspective

Authors: Ishwarlal Jialal

California North State University, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in patients with diabetes. Whilst there are many potential mechanisms including dyslipidemia, hypertension, inflammation and increased oxidative stress, low density lipoprotein- cholesterol (LDL-cholesterol) ranked as the strongest predictor for future cardiovascular events (CVE). Furthermore, numerous trials with statin drugs including HPS-(simvastatin) and CARDS, TNT, PROVE-IT (atorvastatin) have shown a reduction in CV events including ischemic stroke. A meta-analysis of 14 randomized trials showed that statin therapy in diabetics resulted in a 13% reduction in vascular mortality. Numerous guidelines have been issued with respect to statin therapy. The most recent recommendation of the ADA (2016) is high intensity statin (> 50% reduction in LDL-C) for diabetics between ages 40-75 years with ASCVD or ASCVD risk factors (LDL-C>100 mg/dl, hypertension, smoking, obesity, albuminuria FH of premature ASCVD). In this age range, if there is no ASCVD or risk factors moderate intensity statin is recommended (30-50% reduction in LDL-C). In patients > 75 years with ASCVD the only difference is moderate intensity/high intensity statin with ASCVD risk factors. Finally in patients 50% reduction in LDL-C). In the remaining diabetics they recommend a LDL-C goal < 100 mg/ dl. Neither makes a strong recommendation for combination therapy with fibrates and discourages combination with niacin. In conclusion, statin therapy is the cornerstone in our strategy to lower LDL-C to targets or by percentage to reduce ASCVD mortality.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Internal Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternal Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Ishwarlal Jialal”